Burning Rock Biotech Limited (BNR) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Burning Rock Biotech Limited (BNR) Healthcare & Pipeline Overview

Burning Rock Biotech Limited is a China-based precision oncology company specializing in next-generation sequencing (NGS) cancer diagnostic tests. It provides therapy selection and prognosis prediction solutions for a broad spectrum of cancer types, leveraging both tissue and liquid biopsy samples to support clinical decision-making and pharmaceutical research in a rapidly evolving market.

What Is the Investment Thesis for BNR?

Burning Rock Biotech Limited is positioned within the rapidly expanding precision oncology market in China, driven by increasing demand for personalized cancer treatments. The company's comprehensive portfolio of NGS-based cancer therapy selection and prognosis prediction tests, utilizing both tissue and liquid biopsy, addresses a critical need for advanced diagnostics. Strategic collaborations with global pharmaceutical giants like AstraZeneca and Johnson & Johnson enhance its R&D capabilities and market reach, particularly within its Pharma Research and Development Services segment. While the company currently operates with a negative profit margin of -11.5% and a negative ROE of -10.9%, indicating ongoing investment in growth and market penetration, its strong gross margin of 74.6% suggests robust underlying operational efficiency once scale is achieved. The growing adoption of precision medicine in China, coupled with the company's continuous innovation and in-licensing of advanced technologies, presents a significant long-term growth catalyst. However, a high debt-to-equity ratio of 9.85 signals financial leverage that warrants careful monitoring by investors.

Based on FMP financials and quantitative analysis

BNR Key Highlights

• Gross Margin of 74.6% reflects strong operational efficiency in test development and delivery, exceeding many industry benchmarks.
• Profit Margin of -11.5% indicates the company is currently operating at a loss, likely due to significant investments in R&D, market expansion, and infrastructure.
• Return on Equity (ROE) of -10.9% further underscores the company's current unprofitability, with shareholder equity not generating positive returns.
• Market Capitalization of $10.6M positions Burning Rock Biotech as a small-cap company, suggesting higher growth potential but also increased volatility.
• A workforce of 674 employees highlights a substantial operational scale for a specialized biotech firm, supporting its R&D, laboratory operations, and sales efforts across China.

Who Are BNR's Competitors?

BNR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BNR's Key Strengths?

• Comprehensive portfolio of NGS-based cancer diagnostic tests for various cancer types.
• Strategic collaborations with major pharmaceutical companies for R&D and clinical trials.
• High gross margin of 74.6% indicates efficient operational cost management for its services.
• Strong presence and operational infrastructure within the rapidly growing Chinese precision oncology market.

What Are BNR's Weaknesses?

• Persistent negative profit margin (-11.5%) and negative Return on Equity (-10.9%) indicate ongoing unprofitability.
• High debt-to-equity ratio of 9.85 suggests significant financial leverage and potential risk.
• Reliance on the Chinese market exposes the company to specific regional regulatory and economic risks.
• Intense competition from both domestic and international diagnostic companies.

What Could Drive BNR Stock Higher?

• Potential regulatory approvals or expanded reimbursement coverage for its advanced diagnostic tests in key Chinese provinces, driving increased adoption and revenue growth.
• Deepening and expanding collaborations with major pharmaceutical companies for companion diagnostic development and clinical trial support, securing long-term service contracts.
• Continued innovation and launch of new NGS-based liquid biopsy products, capitalizing on the growing preference for non-invasive and comprehensive cancer diagnostics.
• Successful execution of market penetration strategies in underserved regions of China, broadening the company's customer base and increasing test volumes.
• Positive clinical outcomes and data presentations demonstrating the efficacy and utility of Burning Rock's tests, enhancing physician confidence and market demand.

What Are the Key Risks for BNR?

• Financial-distress signal — its Altman Z-Score of -6.31 sits in the distress zone (elevated bankruptcy risk).
• Intense competition within the Chinese precision oncology market from both domestic and international diagnostic companies, potentially leading to pricing pressures and market share erosion.
• Adverse changes in healthcare policies, regulatory frameworks, or reimbursement rates in China, which could significantly impact the company's profitability and operational model.
• Sustained unprofitability and a high debt-to-equity ratio (9.85) pose financial risks, potentially limiting future investment in R&D or market expansion without additional capital.
• Rapid technological advancements by competitors or the emergence of disruptive diagnostic platforms could render Burning Rock's current test portfolio less competitive.
• Exposure to currency fluctuations between the Chinese Yuan and the U.S. Dollar, which can negatively affect the reported financial performance for ADR holders.

What Are the Growth Opportunities for BNR?

• **Expanding Test Portfolio and Indications**: The precision oncology market is continuously evolving with new biomarkers and therapeutic targets. Burning Rock has a significant opportunity to develop and launch new NGS-based tests for additional cancer types or expand the indications for existing tests. This includes enhancing its liquid biopsy offerings, which are less invasive and increasingly preferred. By continuously investing in R&D and leveraging its collaborations, the company can capture a larger share of the diagnostic market, which is projected to grow substantially as more targeted therapies become available, potentially reaching market sizes in the tens of billions globally within the next 5-7 years.
• **Increased Market Penetration in China**: Despite its current presence, the vast and diverse healthcare market in China still offers significant untapped potential for advanced cancer diagnostics. Burning Rock can expand its reach into new geographic regions within China, particularly in tier-2 and tier-3 cities, and increase adoption rates in existing markets. This involves strengthening its in-hospital business segment, building stronger relationships with oncologists, and educating healthcare providers on the benefits of precision oncology. This expansion could drive substantial revenue growth over the next 3-5 years as awareness and accessibility improve.
• **Growth in Pharma Research and Development Services**: Burning Rock's collaborations with major pharmaceutical companies like AstraZeneca and Johnson & Johnson for clinical trials and research studies represent a robust growth avenue. As pharmaceutical companies increasingly focus on developing targeted therapies and require companion diagnostics, the demand for specialized R&D services will rise. Burning Rock can expand its service offerings, attract more pharmaceutical partners, and deepen existing relationships, thereby securing long-term, high-value contracts. This segment is directly tied to the multi-billion dollar global oncology drug development pipeline, offering sustained growth potential over the next decade.
• **Enhanced Adoption of Liquid Biopsy Solutions**: Liquid biopsy, which involves analyzing circulating tumor DNA (ctDNA) from blood samples, is a less invasive alternative to traditional tissue biopsies. The market for liquid biopsy is experiencing rapid growth due to its convenience, ability to monitor treatment response, and utility in cases where tissue biopsy is challenging. Burning Rock's products like OncoCompass IO and OncoCompass Target position it well to capitalize on this trend. Increased adoption of these solutions, driven by clinical evidence and physician preference, could significantly expand its addressable market and revenue streams over the next 2-4 years, as the technology becomes more mainstream.
• **Strategic In-licensing and Partnerships**: The company's strategy of in-licensing advanced technologies, such as Myriad myChoice and DetermaRx, allows it to quickly integrate cutting-edge diagnostics without extensive internal R&D. Continuously seeking and securing similar strategic partnerships for novel technologies or expanding existing agreements can provide Burning Rock with a competitive edge and accelerate its product pipeline. These partnerships can also facilitate market access and technology transfer, enabling the company to offer a broader and more innovative suite of tests, thereby capturing new segments of the precision oncology market over the medium to long term (3-7 years).

What Opportunities Does BNR Have?

• Expanding demand for precision oncology and personalized medicine in China's large patient population.
• Growing adoption of non-invasive liquid biopsy technologies for cancer detection and monitoring.
• Increased partnerships with pharmaceutical companies for companion diagnostics and drug development support.
• Potential for new product launches and expanded test indications to address unmet clinical needs.

What Threats Does BNR Face?

• Rapid technological advancements potentially rendering existing tests obsolete.
• Changes in regulatory policies, reimbursement rates, or pricing pressures in China's healthcare system.
• Intense competition from established and emerging diagnostic companies.
• Intellectual property infringement risks and challenges in a competitive market.
• Currency fluctuations impacting the value of ADRs for U.S. investors.

What Are BNR's Competitive Advantages?

• Proprietary and in-licensed NGS-based test panels covering a broad spectrum of cancer types and biomarkers.
• Extensive clinical data and research collaborations with leading pharmaceutical companies, enhancing test validation and adoption.
• Established operational presence and regulatory expertise within the complex Chinese healthcare market.
• Early mover advantage and strong brand recognition in specific areas of precision oncology diagnostics in China.
• Comprehensive service model spanning central lab, in-hospital, and pharma R&D, offering diverse access points.

What Does BNR Do?

Burning Rock Biotech Limited, established in 2014 and headquartered in Guangzhou, China, is a leading innovator in the field of precision oncology. The company's core business revolves around the development and provision of advanced cancer therapy selection and prognosis prediction tests, primarily utilizing next-generation sequencing (NGS) technology. Burning Rock operates through three distinct segments: its Central Laboratory Business, which processes samples directly; the In-Hospital Business, integrating its testing capabilities within hospital settings; and Pharma Research and Development Services, where it collaborates with pharmaceutical companies on clinical trials and research studies. The company's extensive product portfolio addresses a wide range of cancer types, including lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These tests are performed on both tissue and liquid biopsy samples, offering flexibility and less invasive options for patients. Key products include OncoCompass IO for liquid biopsy, OncoScreen IO as a pan-cancer tissue test, OncoCompass Target for NSCLC ctDNA liquid biopsy, ColonCore for MSI status and gastrointestinal cancer mutations, and the OncoScreen/OncoCompass ParpMatch tests for homologous recombination deficiency. Beyond its proprietary offerings, Burning Rock has strategically expanded its capabilities through in-licensing agreements, such as with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients. The company's commitment to advancing cancer care is further demonstrated by its robust collaborations with major pharmaceutical entities like AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA, facilitating clinical trials and research initiatives.

What Products and Services Does BNR Offer?

• Develops and provides next-generation sequencing (NGS)-based cancer therapy selection tests.
• Offers prognosis prediction tests for various cancer types, aiding treatment decisions.
• Utilizes both tissue and liquid biopsy samples for comprehensive genetic analysis.
• Operates through Central Laboratory, In-Hospital, and Pharma R&D Services segments.
• Provides specific products like OncoCompass IO, OncoScreen IO, OncoCompass Target, and ColonCore.
• Holds in-licensing agreements for advanced tests like Myriad myChoice and DetermaRx in China.
• Collaborates with major pharmaceutical companies on clinical trials and research studies.
• Focuses on a wide range of cancers including lung, gastrointestinal, breast, and prostate.

How Does BNR Make Money?

• Generates revenue from its Central Laboratory Business by processing and analyzing patient samples directly.
• Earns income through its In-Hospital Business by integrating diagnostic testing services within hospital networks.
• Provides Pharma Research and Development Services to pharmaceutical companies, supporting clinical trials and drug development.
• Monetizes its proprietary and in-licensed NGS-based cancer diagnostic tests through service fees.
• Aims to become an integral part of the precision oncology ecosystem in China, offering end-to-end solutions.

What Industry Does BNR Operate In?

Burning Rock Biotech Limited operates within the dynamic and rapidly evolving Medical - Diagnostics & Research industry, specifically focusing on precision oncology in China. This sector is characterized by significant technological advancements, particularly in next-generation sequencing (NGS) and liquid biopsy, which are transforming cancer diagnosis and treatment selection. The global precision oncology market is experiencing substantial growth, with China emerging as a key driver due to its large patient population and increasing healthcare expenditure. Burning Rock is positioned as a prominent player in this market, offering a comprehensive suite of NGS-based tests for various cancer types. The competitive landscape is intense, featuring both domestic and international diagnostic companies vying for market share. Key trends include the shift towards non-invasive liquid biopsy, the integration of diagnostics into therapeutic development, and the growing importance of companion diagnostics for targeted therapies. Burning Rock's strategy of in-licensing advanced technologies and forming collaborations with pharmaceutical companies helps it maintain relevance and competitiveness in this fast-paced environment.

Who Are BNR's Key Customers?

• Oncologists and other medical professionals seeking advanced diagnostic insights for cancer patients.
• Hospitals and clinics requiring comprehensive cancer testing services for their patient populations.
• Cancer patients who benefit from personalized therapy selection and prognosis prediction.
• Pharmaceutical companies collaborating on clinical trials, biomarker discovery, and companion diagnostics.
• Research institutions engaged in oncology studies and drug development.

Company Profile

Burning Rock Biotech Limited operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Guangzhou, CN. The company is led by CEO Yusheng Han. BNR has traded publicly since 2020.

Burning Rock Biotech Limited (BNR) Valuation Context

Relative to its peer group, BNR's quantitative score of 62/100 is roughly in line with the peer average of 53/100.

F-Score 4/9Financial Health

Burning Rock Biotech Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -6.31 places it in the distress zone, a signal of elevated financial risk.

BNR Financials

BNR Latest News

BNR Analyst Consensus

BNR MoonshotScore

BNR Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources